{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"GT Biopharma, Inc."},"Symbol":{"label":"Symbol","value":"GTBP"},"Address":{"label":"Address","value":"9350 WILSHIRE BOULEVARD,SUITE 203, BEVERLY HILLS, California, 90212, United States"},"Phone":{"label":"Phone","value":"+1 800 304-9888"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors."},"CompanyUrl":{"label":"Company Url","value":"https://www.gtbiopharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Michael Breen","title":"Executive Chairman & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}